376 RAD51 RING trial: a European interlaboratory analytical validation to determine the robustness of RAD51 as a biomarker for homologous recombination

C Kramer; A Llop-Guevara; E Yaniz-Galende; B Pellegrino; N Ter Haar; N Campanini; A Musolino; A Leary; M Vreeswijk; V Serra; T Bosse

doi:10.1136/ijgc-2021-ESGO.592

Article info

Translational research biomarkers

376 RAD51 RING trial: a European interlaboratory analytical validation to determine the robustness of RAD51 as a biomarker for homologous recombination

Free

Authors

C Kramer Leiden University Medical Center (LUMC), Pathology, Leiden, Netherlands PubMed articles Google scholar articles
A Llop-Guevara VHIO Vall d’Hebron Institut d’Oncologia, Experimental Therapeutics Group, Barcelona, Spain PubMed articles Google scholar articles
E Yaniz-Galende Hospital Gustave Roussy, Oncological Medicine, Villejuif, France PubMed articles Google scholar articles
B Pellegrino University Hospital of Parma, Medical Oncology and Breast Unit, Medicine , Parma, Italy PubMed articles Google scholar articles
N Ter Haar Leiden University Medical Center (LUMC), Pathology, Leiden, Netherlands PubMed articles Google scholar articles
N Campanini University Hospital of Parma, Medical Oncology and Breast Unit, Medicine , Parma, Italy PubMed articles Google scholar articles
A Musolino University Hospital of Parma, Medical Oncology and Breast Unit, Medicine , Parma, Italy PubMed articles Google scholar articles
A Leary Hospital Gustave Roussy, Oncological Medicine, Villejuif, France PubMed articles Google scholar articles
M Vreeswijk Leiden University Medical Center (LUMC), Human Genetics , Leiden, Netherlands PubMed articles Google scholar articles
V Serra VHIO Vall d’Hebron Institut d’Oncologia, Experimental Therapeutics Group, Barcelona, Spain PubMed articles Google scholar articles
T Bosse Leiden University Medical Center (LUMC), Pathology, Leiden, Netherlands PubMed articles Google scholar articles

Citation

Kramer C, Llop-Guevara A, Yaniz-Galende E, et al

376 RAD51 RING trial: a European interlaboratory analytical validation to determine the robustness of RAD51 as a biomarker for homologous recombination

International Journal of Gynecologic Cancer 2021;31:A333-A334.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password